Weight Loss Medication News

This living topic explores the growing influence of weight loss medications, particularly GLP-1 receptor agonists, on obesity treatment and healthcare access. Key issues include the effectiveness of these drugs, the rising demand for both injectable and oral options, and the financial burden associated with monthly treatment costs, which can exceed $1,000. Articles examine the disparities in access to these medications, regional trends in usage, and the challenges posed by insurance coverage limitations. The topic also delves into concerns surrounding side effects, long-term efficacy, and the evolving landscape of prescription weight loss treatments.

Latest

Lilly reports promising results from its weight-loss drug trial

The company said retatrutide also reduces knee pain in patients

Dec. 11, 2025 By Mark Huffman

Eli Lilly’s experimental weight-loss drug retatrutide led to an average weight reduction of up to 28.7%—more than 71 pounds—in adults with obesity or overweight and knee osteoarthritis.

Participants also saw major reductions in knee pain, with scores on a standard osteoarthritis pain index improving by as much as 76%.

The trial suggests retatrutide may help delay or avoid joint replacement in people with severe obesity and chronic knee pain, though side effects were common...

Read Article